NCT04047797 2025-04-20Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaM.D. Anderson Cancer CenterPhase 2 Terminated3 enrolled 10 charts
NCT04659044 2024-09-19Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaAcademic and Community Cancer Research UnitedPhase 2 Terminated3 enrolled 11 charts